Literature DB >> 2998595

Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis.

S Zucker, R M Lysik, J Wieman, D P Wilkie, B Lane.   

Abstract

In this study we have examined the tissue-destructive proteinases of human pancreatic ductal cancer cell lines derived initially from xenogenic transplants. Cancer cell organelles were isolated following nitrogen cavitation using sucrose density gradient centrifugation. Serine, cysteine, and metalloproteinases were assayed using radiolabeled protein and synthetic substrates. Tumor-induced RBC lysis was quantitated by measuring the release of isotope from 59Fe-labeled RBCs co-cultivated with tumor cells or subcellular fractions. Enzyme inhibitors with specificity toward different classes of proteinases were used in the above assays to categorize the enzymes responsible for substrate degradation. Results indicated that intact pancreatic cancer cells (RWP-1 and RWP-2 cell lines), cell homogenate, and cytosol contain proteinases which were able to degrade [3H]collagen (type I) and [3H]gelatin and lyse normal RBCs. Cancer cell membrane fractions were enriched in collagenolytic, gelatinolytic, and cytolytic activities which could be abrogated by EDTA but not by inhibitors of serine or cysteine proteinases, which indicates that metalloproteinases are the active enzymes in these assays. Although plasminogen activator and cysteine proteinases were also enriched in the tumor cell membranes, these activities were not required for collagen degradation or cytolysis. We conclude that human cancer cell membrane proteinases are advantageously situated to facilitate damage to surrounding normal tissues.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998595

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

Review 2.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

3.  Characterization of a connective tissue degrading metalloproteinase from human small cell lung cancer cells.

Authors:  S Zucker; T Turpeeniemi-Hujanen; J M Wieman; R M Lysik
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

4.  Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors.

Authors:  Z L Gokaslan; S K Chintala; J E York; V Boyapati; S Jasti; R Sawaya; G Fuller; D M Wildrick; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

5.  Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?

Authors:  Stanley Zucker; Jian Cao
Journal:  Cancer Biol Ther       Date:  2009-12-19       Impact factor: 4.742

6.  Cathepsin B expression in tumour cells and laminin distribution in pulmonary adenocarcinoma.

Authors:  M Higashiyama; O Doi; K Kodama; H Yokouchi; R Tateishi
Journal:  J Clin Pathol       Date:  1993-01       Impact factor: 3.411

7.  Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays.

Authors:  S Zucker; P Mancuso; B DiMassimo; R M Lysik; C Conner; C L Wu
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

8.  Purification and characterisation of soluble tumour haemolytic factor isolated from oncogene transformed fibroblasts.

Authors:  S Zucker; J Wieman; R M Lysik; B Imhof; A A Farooqui
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.